openPR Logo
Press release

Global Controlled Release Drug Delivery Market Opportunity and Clinical Trial Outlook 2025

11-23-2018 12:50 PM CET | Health & Medicine

Press release from: KuicK Research

Global Controlled Release Drug Delivery Market Opportunity

"Global Controlled Release Drug Delivery Market Opportunity and Clinical Trial Outlook 2025" Report Highlights:

Development of Controlled Release Drug Delivery Technology
Approaches for Controlled Release Drug Delivery
Global Controlled Release Drug Clinical Pipeline by Phase, Indication, Drug Class
Global Controlled Release Drug Clinical Pipeline: 218 Drugs
Marketed Controlled Release Drugs: 118 Drugs
Majority Drugs In Phase-II and Phase-III Trials: More Than 80
Global Controlled Release Drug Delivery Market Future Outlook

Controlled Release drug delivery technology is the one of the most rapidly advancing area in human healthcare management and already had an enormous impact on medical technology with the potential to improve health. As the goal of any drug delivery system is to provide a therapeutic amount of drug to a proper site in the body so that the desired drug concentration can be achieved promptly and then maintained, all these characteristics are provided by controlled drug delivery technologies.

Controlled Release drug delivery systems provide uniform concentration of drug to the absorptions site and thus allow the maintenance of plasma concentration within the therapeutic range which minimizes not only the side effects but also the frequency of administration. The term controlled release has a meaning that goes beyond the scope of sustained drug action.

One of the major factors for the increased market tendencies for controlled release drug delivery market is the improvement and advances in the use of varied approaches. Polymeric controlled release drug delivery is the most applied strategy towards the controlled release drug delivery. Polymers used for coating and in other forms consist of two forms synthetic and biodegradable polymers. The extensive usage of biodegradable polymers in medical devices is expected to push the global biodegradable polymers market.

The future of controlled release drug delivery is quite fertile with respect to various upcoming systems and products which will be providing the controlled release mechanism. Some of the products have been launched and some will be coming soon as are under clinical investigations. Various depot systems are under construction, along with the approaches using nanoparticulate system, transdermal controlled deliveries and much more. Newer, more sophisticated, transdermal patches and other transdermal controlled release drug delivery systems are being developed that are currently being tested in clinical trials.

KuicK Research report on the "Controlled Release Drug Delivery Market" is a result of intensive study of the novel segment and its future market potential. The report has been made with key focus on the current market trends, superiority of Controlled Release Drug Delivery methods to traditional drug delivery methods. The report also provides key insights into the technology and approaches of controlled delivered drugs, recent developments and market dynamics that might impact its future. The report concludes with comprehensive insight on ongoing clinical trials of controlled delivered drugs and future trends which clearly highlights it as one of the most promising market in the modern drug delivery segment.

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

Download Report: https://www.kuickresearch.com/report-global-controlled-release-drug-delivery-market-opportunity--and-clinical-trial-outlook-2025.php

Report Table of Contents

1. Drug Delivery: An Advancing Trajectory
1.1 Preamble Towards Drug Delivery
1.2 Ideal Mode of Drug Delivery System

2. What is Controlled Release Drug Delivery?
2.1 Novel Drug Delivery Systems
2.2 Preamble to Controlled Release Drug Delivery

3. Development of Controlled Release Drug Delivery Technology
3.1 First Generation
3.2 Second Generation

4. Basics of Controlled Release Drug Delivery
4.1 Prerequisites of Controlled Release Delivery
4.2 Rationale for Controlled Release Drug Delivery

5. Mechanism of Controlled Drug Release
5.1 Diffusion Controlled
5.2 Dissolution Controlled System
5.3 Water Penetration Controlled System
5.4 Erosion Controlled System
5.5 Ion-Exchange Controlled System

6. Cataloging of Controlled Release Drug Delivery
6.1 Classification Based Over Delivery Systems
6.2 Classification Based Over Technicality
6.3 Classification Based Over Routes

7. Approaches for Controlled Release Drug Delivery
7.1 Polymers
7.2 Chronopharmaceutics
7.3 Nanoparticulate Delivery System

8. Global Controlled Release Drug Clinical Pipeline Overview
8.1 Phase
8.2 Country/Region
8.3 Mode of Action
8.4 Drug class
8.5 Indication

9. Application of Controlled Release Drug Delivery
9.1 Diabetes
9.2 Cancer
9.3 Cardiovascular Diseases
9.4 Neurological Disorders
9.5 Infections

10. Drug Designing for Controlled Release Delivery
10.1 Enteral Dosage Formulations
10.1.1 Solid Dosage Forms
10.1.2 Liquid Dosage Forms
10.1.3 Inhalation Dosage Forms
10.2 Parenteral Dosage Forms
10.2.1 Injectable Dosage Forms
10.2.2 Implantable Device
10.3 General Mechanisms of Drug Release

11. Market Inclinations
11.1 Market over Routes of Administration
11.2 Market over Approaches

12. Global Controlled ReleaseDrug Delivery Market Dynamics
12.1 Accelerative Parameters
12.2 Challenges

13. Global Controlled Drug Release Delivery Market Future Outlook
13.1 Ongoing Clinical Trials
13.2 Future Market Opportunities

14. Global Controlled Release Drug Delivery Clinical Trials by Company, Indication and Phase
14.1 Unknown
14.2 Research
14.3 Preclinical
14.4 Clinical
14.5 Phase-I
14.6 Phase-I/II
14.7 Phase-II
14.8 Phase-II/III
14.9 Phase-III
14.10 Preregistration
14.11 Registered

15. Marketed Controlled Release Drug Clinical Insight by Company, Indication and Phase

16. Competitive Landscape
16.1 Allergan
16.2 Amylin Pharmaceuticals
16.3 AstraZeneca
16.4 BioAlliance Pharma
16.5 Biogen
16.6 Collegium Pharmaceutical
16.7 Controlled Therapeutics (Ferring Pharmaceuticals)
16.8 Cosmo Pharmaceuticals
16.9 Egalet
16.10 Elan Corporation
16.11 Encore Therapeutics
16.12 Flamel Technologies
16.13 GlaxoSmithKline
16.14 Heron Therapeutics
16.15 iCeutica
16.16 Mithra Pharmaceuticals
16.17 Neurim Pharmaceuticals
16.18 Novartis
16.19 Orexigen Therapeutics
16.20 Otsuka Pharmaceutical
16.21 Pfizer
16.22 Purdue Pharma
16.23 Syntex Pharmaceuticals International
16.24 Takeda
16.25 Zealand Pharma

Figure 1-1: Characteristics of an Ideal Drug Delivery System
Figure 2-1: Limitations of the Conventional Drug Delivery Systems
Figure 2-2: Diversification of the Novel Drug Delivery Platforms
Figure 3-1: History of Drug Delivery Technology from First Generation till Third Generation
Figure 3-2: Barriers to be Overcome by the Third Generation Drug Delivery System
Figure 4-1: Demonstration of the Targeted and Non-Targeted Drug Delivery
Figure 4-2: Controlled Drug Release is by Zero Order Mechanism
Figure 5-1: Differentiation of the Two Forms of the Diffusion Controlled Mechanisms
Figure 5-2: Mechanism of Encapsulation Dissolution Controlled System
Figure 5-3: Osmotic Release of the Drug Delivery with the Controlled Mechanism
Figure 5-4: Illustration of Erosion Mechanisms Found in Matrix Systems
Figure 6-1: Plasma Concentration v/s Time Profile in Conventional and Controlled Release
Figure 6-2: Comparison of Varied Modified Drug Release Systems
Figure 6-3: Illustration of Mechanism of Pulsatile Drug Release in Pulsincap
Figure 6-4: Classification Based Over the Technicality Erudition
Figure 6-5: Structural Differentiation among Varied Classified Drug Delivery Systems
Figure 6-6: Classification Based over the Route of Administration
Figure 7-1: Categorization of Polymeric Controlled Drug Delivery Devices
Figure 7-2: Varied Nanostructures Available for the Nanoparticulate Delivery System
Figure 8-1: Global - Controlled Release Drug Clinical Pipeline by Phase (%), 2018 till 2025
Figure 8-2: Global - Controlled Release Drug Clinical Pipeline by Phase (Number), 2018 till 2025
Figure 8-3: Global - Controlled Release Drug Clinical Pipeline by Phase (%),2018 till 2025
Figure 8-4: Global - Controlled Release Drug Clinical Pipeline by Phase (Number), 2018 till 2025
Figure 8-5: Global - Controlled Release Drug Clinical Pipeline by Country/Region (Number),2018 till 2025
Figure 8-6: Global - Controlled Release Clinical Drug Pipeline by Mode of Action (Number), 2018 till 2025
Figure 8-7: Global - Controlled Release Drug Clinical Pipeline by Drug Class (Number), 2018 till 2025
Figure 8-8: Global - Controlled Release Drug Clinical Pipeline by indication (Number), 2018 till 2025
Figure 9-1: Major Non-Invasive Administrative Routes of Insulin Delivery
Figure 9-2: Layout of the Controlled Drug Delivery Approaches in Cancer Therapeutics
Figure 9-3: Controlled Drug Delivery Approaches used to Deliver Drugs to CNS
Figure 10-1: Dosage Formulations for the Controlled Drug Delivery
Figure 10-2: Mechanism of the Controlled Drug Release of the Solid Dosage Forms
Figure 10-3: Representation of Categories of Liquid Dosage Form
Figure 10-4: Mechanism of Controlled Delivery of Parenteral Dosage Forms
Figure 10-5: General Forms of Oral Controlled Release System Mechanism
Figure 10-6: Schematic Diffusion Controlled Drug Release from Inert Matrices
Figure 10-7: Demonstration of the Osmotic Pump Drug Release Mechanism
Figure 11-1: Drug Delivery Share by Route of Administration, 2016
Figure 11-2: Global - Oral Drug Delivery Administration Market (US$ Billion), 2017 and 2025
Figure 11-3: Global - Injectable Drug Delivery Systems Market (US$ Billion), 2017 and 2025
Figure 11-4: Global - Implantable Device Market (US$ Billion), 2017 and 2025
Figure 11-5: Global - Topical Drug Delivery System Market (US$ Billions), 2017 and 2025
Figure 11-6: Global - Biodegradable Polymer Market (US$ Billions), 2017 and 2025
Figure 11-7: Global - Smart Polymers Market (US$ Billion), 2017 and 2025
Figure 11-8: Global - Nanomedicine Market (US$ Billion), 2017-2025
Figure 12-1: Accelerative Parameters of Controlled Drug Delivery Systems
Figure 12-2: Major Challenges Faced by Controlled Drug Delivery System
Figure 13-1: Illustration of Clinical Trials in Varied Segments for Controlled Drug Delivery

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Controlled Release Drug Delivery Market Opportunity and Clinical Trial Outlook 2025 here

News-ID: 1395353 • Views:

More Releases from KuicK Research

Global Peptide Cancer Drug Oncology Therapeutics Market Clinical Trial Report 2026
Global Peptide Cancer Drug Oncology Therapeutics Market Clinical Trial Report 20 …
"Global Peptide Cancer Therapeutics Market, Drug Dosage, Price and Clinical Trials Insight 2026" Report highlights: • Global cancer Peptide Market Opportunity: > US$ 20 Billion By 2026 • Price, Dosage, Sales Insight On 22 Marketed Cancer Peptides • Global Peptide Cancer Therapeutics Clinical Trials Overview by Company, Country, Indication, Phase & Formulation • Comprehensive Clinical Insight On More Than 150 Cancer Peptides In Clinical Trials • Comprehensive Clinical Insight On More Than 20 Cancer Peptides Available In Market • Application of
Global Cancer Immunotherapy Market Opportunity Market Size Clinial Pipeline Tria …
The research report "Global Cancer Immunotherapy Market Opportunity, Dosage, Price & Clinical Trials Insight 2026" aims at providing a comprehensive analysis about the overall market trends in the global cancer immunotherapy market. The report also discusses the insights of the various methodologies that the therapy has presented over the last few decades. In addition to the recent appreciation that the therapy is gaining in the market, the report also covers
Global Cancer Generics Drug Market Pricing Dosage Size Insight By Countries Drug …
The research report "Global Cancer Generics Market, Drug Dosage, Price and Opportunity Insight 2026" provides a comprehensive view about the recent trends and opportunities that are followed by the market at the level of regional and global. The study majorly focuses on the strategies that have been adopted by several players in revolutionizing the market and making the clinicians and non-clinicians more inclined towards adopting generic drugs. In addition to
Global Cancer Stem Cell Clinical Trials Has More Than 35 Therapies In Pipeline
"Global Cancer Stem Cell Therapy Market, Price, Dosage & Clinical Trial Insight 2025" Report Highlights: o Role & Mechanism Of Stem Cells In Cancer Treatment o Stem Cell Transplantation In Cancer Treatment o Global Bone Marrow Transplant Market Opportunity : > US$ 15 Billion o Global Cord Blood Transplant Market Opportunity o Cancer Stem Cell Therapy Clinical Pipeline: 37 Therapies o Majority Stem Cells In Preclinical Phase: 18 Therapies o Cancer Stem Cell Therapy Clinical Pipeline by Country: More Than 30 In USA o Post Therapy

All 5 Releases


More Releases for Drug

Alcohol Testing And Drug Testing Equipment Market 2025 Segmentation, Application …
Market Study Report, LLC, has compiled an exhaustive research study of the ‘Alcohol Testing And Drug Testing Equipment market’, detailing every single market driver and intricately analyzing the business vertical. This ‘Alcohol Testing And Drug Testing Equipment market’ study will aid in seeking out new business opportunities and fine-tuning existing marketing strategies through insights regarding SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions. Alcohol abuse and drug
How much Diabetes Drug Market Impact Worldwide Medical Drug Industry?
Diabetes Drug Market From an insight perspective, the market report focuses on various levels of analyses — industry analysis, market rank analysis, and company profiles, which together comprise and discuss basic views on the competitive landscape, high-growth regions, and countries as well as their respective regulatory policies, Types ,Applications and opportunities in the market.  Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two types of diabetes
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning
Drug Discovery Strategies, PBPK Modeling and Drug-Drug Interaction Explored and …
This year’s 12th annual ADMET conference and exhibition promises to deliver appearances from experienced pharmaceutical professionals from ADME and PK/PD organisations such as AbbVie, GSK, Roche and Bayer when it returns to London this June. The carefully selected speaker line up will be addressing early ADME application strategies and discussing the latest technologically advanced screening and testing models along with exploring ADMET technologies which will identify properties of a drug